SLC5A2 and hepatocellular carcinoma: Similar findings have been made in clinical studies (Akuta et al., 2019; Takahashi et al., 2022). In essence, CANA induces cell cycle arrest and apoptosis in hepatocellular carcinoma, while also inhibiting tumor growth by directly inhibiting SGLT-2 in tumor cells.